
Embolization

 
Embolization requires snaking a catheter [ a long narrow tube] into the small arteries feeding a tumor, and then injecting particles into that small artery.  The particles clog up the arteries, and clots form.  This robs the tumor of its blood supply, so it can die.  It also cuts off possible areas of bleeding if used preoperatively in hypervascular tumors.  Operating on very vascular tumors usually means there is heavy bleeding, because the area becomes very vascularized with a high blood flow.  So embolization can either directly attack a tumor so that it dies back, and stops eroding bone, or it can be used to decrease blood flow to the area, allowing cleaner removal of tumor with less blood loss.
''The technique of selective embolization has been in use for years in the treatment of vascular anomalies, severe hemorrhage and benign or malignant tumors, notably renal cell cancer vertebral metastases. Because this technique is relatively easy to perform and can offer immediate relief of symptoms, it is an attractive option for patients with hypervascular vertebral metastases with signs of spinal cord compression. Selective catheterization of the arteries feeding the metastases is performed, followed by infusion of polyvinyl alcohol particles.  Embolization results in rapid resolution of neurological symptoms, sometimes within hours. The therapeutic effect lasts from months to years. Embolization of hypervascular vertebral metastases is a palliative therapeutic option that may offer rapid relief of symptoms.''[44]
Embolization can also stop tumors from bleeding spontaneously.  "Embolization therapy is reported in three patients bleeding from metastatic carcinoma of the breast. Two had life threatening hemorrhage from sternal erosion;.... The third patient had intermittent bleeding of extensive fungating axillary and anterior chest wall metastases. Autologous clot alone was used in the first case with immediate cessation of bleeding and transient neurological symptoms secondary to back flow of thrombus into the vertebral artery were noted. The second and third patients received Oxycel-Ivalon and Gel-foam respectively; bleeding ceased and no complications were noted." [15]
Embolization alone can often reduce metastatic spinal cord compression, so surgical decompression is either not necessary or can be postponed. [7,11, 12]
Massive perioperative hemorrhage is often associated with surgery for vertebral metastases. Preoperative embolization reduces operative blood loss so that  hypervascular tumors may be removed safely after embolization.  The resulting devascularization allows for an aggressive resection of pathologic tissue [4,5,6,8,18,57,72,87] 
Access to PubMed Search & Obtaining Abstracts of the Medical Journal Articles:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=PubMed&term=bone%20metastasis%20embolization
Chemoembolization
 Chemoembolization [also called transcatheter arterial embolization] consists of embolization, as described above, with specific catheterization of the artery or arteries supplying the tumor.  But the embolization is with gelatin sponge particles, which are impregnated with chemotherapy agents.  Thus the chemo agents remain in contact with the tumor at higher concentrations than would be possible systemically.  Doxorubicin is one of the agents frequently used this way.  This modality can be combined with RFA hyperthermia, and/or radiotherapy. [22]  For more information about chemoembolization and transcatheter arterial embolization [T.A.E.] see the section under Liver Metastases.
        

Radioisotope Embolization  [Theraspheres]

This would be a technique whereby the selective catheterization of tumor-supplying arteries would result in embolization of the arteries with either glass beads or resin impregnated with Yttrium-90. This would result in the radiation being discharged locally in the tumor.  Currently this technique is only under investigation for treatment of liver metastases, not bone metastases.   However, it would seem to lend itself to treatment of bone metastases.   For more information, see the Liver Metastasis section of this website.

The question of whether Theraspheres [glass beads] or resinous beads are used may be decided by whether the radioisotope remains within the delivery system or whether it leaches out into the systemic circulation.  Whether the presence of the glass or resin will prevent subsequent RFA treatment of the area, or the presence of the Yttrium-90 prevent use of other agents subsequently is not known.  


Go To Top
References for this Section:
4: Breslau J, Eskridge JM. Preoperative embolization of spinal tumors. J Vasc Interv Radiol 1995 Nov-Dec;6(6):871-5
5: Mori K, Yamada S, Kosaka A, et. al., A case of liver metastases from leiomyosarcoma in the chest wall which was made resectable by chemoembolization.  Gan To Kagaku Ryoho 1997 Sep;24(12):1741-4
6: Griffith JF, Kumta SM. Clinics in diagnostic imaging (25). Aggressive vertebral haemangioma. Singapore Med J 1997 May;38(5):226-30 
7: Ikejiri K, Furuyama M, Muranaka T, Anai H, Takeo S, Sakai K, Saku M, Yoshida K. Carcinoma of the thyroid manifested as hyperthyroidism caused by functional bone metastasis. Clin Nucl Med 1997 Apr;22(4):227-30 
8: Olerud C, Jonsson B. Surgical palliation of symptomatic spinal metastases. Acta Orthop Scand 1996 Oct;67(5):513-22
11. O'Reilly GV, Kleefield J, Klein LA, Blume HW, Dubuisson D, Cosgrove GR. Embolization of solitary spinal metastases from renal cell carcinoma: alternative therapy for spinal cord or nerve root compression. PMID: 2928919 [PubMed - indexed for MEDLINE] 
12: Taki Y, Yamaoka Y, Takayasu T, Ino K, Shimahara Y, Mori K, Morimoto T, Ozawa K. Bone metastases of hepatocellular carcinoma after liver resection.  J Surg Oncol 1992 May;50(1):12-8 
15: Harrington DP, Barth KH, Baker RR, Truax BT, Abeloff MD, White RI Jr. Therapeutic embolization for hemorrhage from locally recurrent cancer of the breast. Radiology 1978 Nov;129(2):307-10 
18: Bilsky MH, Boland P, Lis E, Raizer JJ, Healey JH. Single-stage posterolateral transpedicle approach for spondylectomy, epidural decompression, and circumferential fusion of spinal metastases. Spine 2000 Sep 1;25(17):2240-9,discussion 250 
22: Nagata Y, Mitsumori M, Okajima K, Mizowaki T,et.al., Transcatheter arterial embolization for malignant osseous and soft tissue sarcomas. II. Clinical results.Cardiovasc Intervent Radiol 1998 May-Jun;21(3):208-13 
44: Smit JW, Vielvoye GJ, Goslings BM, Embolization for vertebral metastases of follicular thyroid carcinoma.  J Clin Endocrinol Metab 2000 Mar;85(3):989-9457: Berkefeld J, Scale D, Kirchner J, Heinrich T, Kollath J., Hypervascular spinal tumors: influence of the embolization technique on perioperative hemorrhage. AJNR Am J Neuroradiol 1999 May;20(5):757-63  
72: Taniguchi T, Ohta K, Ohmura S, Yamamoto K, Kobayashi T. Perioperative management for total en bloc spondylectomy--the effects of preoperative embolization and hypotensive anesthesia Masui 2000 Feb;49(2):168-71 
87: Choi IS, Tantivatana J. Neuroendovascular management of intracranial and spinal tumors. Neurosurg Clin N Am 2000 Jan;11(1):167-85


Further References Obtained from a Review Article

  1.. Luessenhop AJ, Kachmann R, Shevlin W. 1965 Clinical evaluation of artificial embolization in the management of large cerebral arteriovenous malformations. J Neurosurg. 23:400. 
  2.. Gomes AS, Busuttil RW, Baker JD, Oppenheim W, Machleder HI, Moore WS. 1983 Congenital arteriovenous malformations. The role of transcatheter arterial embolization. Arch Surg. 118:817-825.[Medline] 
  3.. Dawson RC, Joseph GJ, Owens DS, Barrow DL. 1998 Transvenous embolization as the primary therapy for arteriovenous fistulas of the lateral and sigmoid sinuses. Am J Neuroradiol. 19:571-576.[Abstract] 
  4.. Hekster RE, Luyendijk W, Tan TI. 1972 Spinal-cord compression caused by vertebral haemangioma relieved by percutaneous catheter embolisation. Neuroradiology. 3:160-164.[Medline] 
  5.. Hekster RE, Endtz LJ. 1987 Spinal-cord compression caused by vertebral haemangioma relieved by percutaneous catheter embolisation: 15 years later. Neuroradiology. 29:101.[Medline] 
  6.. Guibaud L, Herbreteau D, Dubois J, et al. 1998 Aneurysmal bone cysts: percutaneous embolization with an alcoholic solution of zein-series of 18 cases. Radiology. 208:369-373.[Abstract] 
  7.. Ravina JH, Herbreteau D, Ciraru-Vigneron N, et al. 1995 Arterial embolisation to treat uterine myomata. Lancet. 346:671-672.[Medline] 
  8.. Gold RE, Grace DM. 1975 Gelfoam embolization of the left gastric artery for bleeding ulcer: experimental considerations. Radiology. 116:575-580.[Abstract] 
  9.. Valavanis A. 1986 Preoperative embolization of the head and neck: indications, patient selection, goals, and precautions. Am J Neuroradiol. 7:943-952.[Abstract] 
  10.. Casasco A, Herbreteau D, Houdart E, et al. 1994 Devascularization of craniofacial tumors by percutaneous tumor puncture. Am J Neuroradiol. 15:1233-1239.[Abstract] 
  11.. Smith TP, Gray L, Weinstein JN, Richardson WJ, Payne CS. 1995 Preoperative transarterial embolization of spinal column neoplasms. J Vasc Interv Radiol. 6:863-869.[Abstract] 
  12.. Barton PP, Waneck RE, Karnel FJ, Ritschl P, Kramer J, Lechner GL. 1996 Embolization of bone metastases. J Vasc Interv Radiol. 7:81-88.[Abstract] 
  13.. Gellad FE, Sadato N, Numaguchi Y, Levine AM. 1990 Vascular metastatic lesions of the spine: preoperative embolization. Radiology. 176:683-686.[Abstract] 
  14.. Hess T, Kramann B, Schmidt E, Rupp S. 1997 Use of preoperative vascular embolisation in spinal metastasis resection. Arch Orthop Trauma Surg. 116:279-282.[Medline] 
  15.. O'Reilly GV, Kleefield J, Klein LA, Blume HW, Dubuisson D, Cosgrove GR. 1989 Embolization of solitary spinal metastases from renal cell carcinoma: alternative therapy for spinal cord or nerve root compression. Surg Neurol. 31:268-271.[Medline] 
  16.. Sundaresan N, Choi IS, Hughes JE, Sachdev VP, Berenstein A. 1990 Treatment of spinal metastases from kidney cancer by presurgical embolization and resection. J Neurosurg. 73:548-554.[Medline] 
  17.. Sun S, Lang EV. 1998 Bone metastases from renal cell carcinoma: preoperative embolization. J Vasc Interv Radiol. 9:263-269.[Abstract] 
  18.. Wallace S, Chuang VP, Swanson D, et al. 1981 Embolization of renal carcinoma. Radiology. 138:563-570.[Abstract] 
  19.. Chuang VP, Soo CS, Wallace S. 1981 Ivalon embolization in abdominal neoplasms. Am J Roentgenol. 136:729-733. 
  20.. Wallace S, Charnsangavej C, Carrasco CH, Bechtel W. 1984 Infusion-embolization. Cancer. 54:2751-2765.[Medline] 
  21.. Tadavarthy SM, Moller JH, Amplatz K. 1975 Polyvinyl alcohol (Ivalon)-a new embolic material. Am J Roentgenol Radium Ther Nucl Med. 125:609-616.[Medline] 
  22.. Camille RR, Leger FA, Merland JJ, Saillant G, Savoie JC, Riche MC. 1980 Recent advances in the treatment of bone metastases from cancer of the thyroid (author's translation). Chirurgie. 106:32-36.[Medline] 
  23.. Ripp GA, Wendth AJJ, Vitale P. 1977 Metastatic thyroid carcinoma of the mandible mimicking an arteriovenous malformation. J Oral Surg. 35:743-745.[Medline] 
  24.. Monteil JP, Houlbert D, Saliba N, Despreaux G, Tran BH. 1985 Cranial and cervical metastases of vascular nature in thyroid cancer. Apropos of 2 cases. Ann Otolaryngol Chir Cervicofac. 102:53-57.[Medline] 
  25.. Yamasoba T, Kikuchi S, Sugasawa M, Higo R, Sasaki T. 1994 Occult follicular carcinoma metastasizing to the sinonasal tract. ORL J Otorhinolaryngol Relat Spec. 56:239-243.[Medline] 
  26.. Chuang VP, Wallace S, Swanson D, et al. 1979 Arterial occlusion in the management of pain from metastatic renal carcinoma. Radiology. 133:611-614.[Abstract] 
  27.. Hermanek P, Sobin LH. 1992 Thyroid gland (ICD-OC73). TNM classification of malignant tumors, 4th ed, 2nd rev. International Union Against Cancer. Berlin: Springer Verlag; 35-37. 
  28.. Goslings BM. 1975 Proceedings: effect of a low iodine diet on 131-I therapy in follicular thyroid carcinomata. J Endocrinol. 64:30P. 
  29.. Schlumberger M, Challeton C, De Vathaire F, et al. 1996 Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med. 37:598-605.[Abstract] 
  30.. Pelikan DM, Lion HL, Hermans J, Goslings BM. 1997 The role of radioactive iodine in the treatment of advanced differentiated thyroid carcinoma. Clin Endocrinol (Oxf.).47 :713-720. 
  31.. Rockwell S. 1997 Oxygen delivery: implications for the biology and therapy of solid tumors. Oncol Res. 9:383-390.[Medline] 



Go To Top


~~~~~~~~~~~~~~~~~~~~~~~~~~~

RADIOISOTOPES


Radioisotope Use In Cancer Metastatic to Bone
Radiosensitization
Strontium-89
Samarium-153
Rhenium-186
Phosphorus-32
Comparisons of RadioIsotopes
References

Radioisotope Use In Cancer Metastatic to Bone
        Bone pain is a common symptom in disseminated malignancy and may be difficult to manage effectively.  Pain caused by multiple bone metastases is treated by non-steroidal anti-inflammatory drugs and opioid-containing analgesics. Radiation is also of proven benefit for palliation of painful bony tumors.  There is growing interest in the therapeutic potential of bone-seeking radiopharmaceuticals that selectively irradiate the bone metastases while sparing healthy surrounding tissue. The radioisotope would be present in a higher concentration for a longer period of time at the tumor.   The response rate is roughly 70 to 80% of the patients treated. Pain relief may last for between 1 and 6 months, with the option of multiple treatments.  Response to additional treatments may not be as good as initial response. The prognosis of the disease is, however, usually not affected.[25,26] Patients with a positive bone scan using technetium 99m methylene diphosphonate (Tc-99-MDP) are eligible for treatment.  Although we can predict nonresponders, we cannot predict responders; however, patients with a better performance scale may have a better chance of pain relief. [120]

For patients with symptomatic widespread bone metastases, options include bisphosphonates or radiotherapy.  There are two forms of systemic radiotherapy available: hemibody irradiation and intravenous injection of radionuclides. Studies have shown the combination of either focal irradiation and hemibody irradiation or focal irradiation and the injection of strontium (89) prolongs the pain-free duration of the patients. [125]
               

Phosphorus-32, strontium-89, samarium-153 EDTMP, rhenium-186 HEDP and tin-117m DTPA have all been used effectively for bone pain palliation. [15,20,21,25,53,120] Each of these agents and/or radionuclides has specific advantages and disadvantages; however, the ideal agent for bone pain palliation has not yet been identified. [20,38,120] Systemic radionuclide therapy has two major advantages: 
(i) It addresses all sites of involvement; and  
(ii) 	      Selective absorption limits normal tissue dose. As a result, toxicity is reduced and the therapeutic ratio 
                  increased. 

It is also particularly useful when external beam therapy options have been exhausted, and normal tissue tolerance has been reached.  Prophylactic administration of systemic radionuclides for clinically occult metastases might delay their appearance [prostate cancer]. Often the isotope works better with a radiosensitizer [e.g. low dose cisplatin] , allowing for longer effectiveness, decreased growth and/or slowed progression of disease.  When the effect of the radioisotope wears off, and pain returns, repeat injections can be given, with repeat response [but it may not be so effective as initial response.]  Radioisotopes can also be used as part of a multi-modality approach, with significant chemotherapy.  Research is also indicated to compare treatment with radioisotopes and bisphosphonates, and to see whether they might work well together.  [9,51]

Pain palliation with bone-seeking radiopharmaceuticals is an effective and cost-effective management tool in patients with advanced cancer metastatic to bone. Strontium-89 (Metastron) and samarium-153-EDTMP (Lexidronam) are licensed for use in patients in the United States. Patients with a positive bone scan using technetium 99m methylene diphosphonate (Tc-99-MDP) are eligible for treatment, and indications and contraindications for use are now well defined. Evidence now suggests that the radiopharmaceuticals can reduce pain and analgesic requirements, improve quality of life, reduce lifetime radiotherapy requirements and management costs, and may slow the progression of painful metastatic lesions. Retreatment is possible and effective. 

Although sarcomas are relatively radioresistant, the total focal dose may be VERY high IF the tumor preferentially takes up the radioisotope. A very high dose might delay local progression or even achieve permanent local tumor control in patients with surgically inaccessible primary or relapsing osteoblastic tumors. [4,6,49]  

However, also because of their uptake in bone, treatment or repeated treatment of bone tumors by radioisotopes often results in myelodysplasia.  The bone marrow is exposed to radiation in higher doses and for longer periods by bone seeking radioisotopes.  A very high local dose can also cause bone marrow damage, so patients with extensive bone marrow invasion of tumor should be watched carefully as they are at high risk. [126]

  Use of radioisotope treatment repeatedly, or concomitantly with, or additionally to chemotherapy or radiation puts patients at high risk of bone marrow failure.  Stem Cell Harvesting and Autologous Re-Transfusion is a process that should be considered prior to instituting treatment in this case. [6] Other than myelodysplasia, the early side effect profile is negligible.[4]   Late effects [long term permanent damage] are not completely known, but are probably related to bone marrow damage and new primary cancers.  Skeletal doses of this order of magnitude are also known to be osteosarcomogenic [49,107] and probably leukemogenic [121] in humans when given as Strontium-90 injections.  

Generally, toxicity the flare phenomenon and myelosuppression, especially white cells and platelets--treatments should not be given to patients with suspected disseminated intravascular coagulation [can cause severe, life-threatening platelet loss]. [15,20,23,50, 120]   The Society of Nuclear Medicine's bone pain treatment procedure guideline states that patients referred for bone palliation should be screened for disseminated intravascular coagulation before therapy. [PMID: 10551466] 

Without Stem Cell conservation and re-transfusion, radioisotope treatment of LMS bone lesions might result in myelodysplasia after only one treatment, because of previous chemotherapy having been given in the usual very high dosage range that LMS requires.   Therefore, it might limit further chemotherapy.  
Surgery remains the treatment of choice. When surgery is not possible, then irradiation of the tumor, and possibly radioisotope treatment, might be used for palliation.  However, Stem Cell Harvesting and Autologous Retransfusion should be considered if radioisotope treatment of bone lesions is adopted. [3,4,6]  Radioisotopes seem to work best in prostate and breast cancer secondaries.  Although there is sometimes a response from other, lytic, cancers, the best responses come from these groups.  [117]
              

Radioisotope treatment is palliative, not curative, and might limit future chemotherapy treatments.



Pubmed search link:  Treatment of bone cancer with radioisotopes.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=PubMed&term=bone%20radioisotope%20cancer%20treatment



About Radiosensitization

Intravenous outpatient radiopharmaceuticals have proven effective in treating pain associated with multiple osteoblastic bony metastasis from prostate or breast cancer. Radiosensitizers such as idoxyuridine incorporate into the DNA and increase the susceptibility of the cancer cell to radiation damage. Hypoxic cell sensitizers (such as metronidazole, misonidazole, SR 2508, and Ro-038799) increase oxygen to the cancer hypoxic cells and promote damage of the DNA, thus preventing cell repair. [Otto SE. J Intraven Nurs 1998 Nov-Dec;21(6):335-7. PMID: 10392098 ] 
              
This study reports on two preliminary experiences with low-dose platinum compounds, carboplatin and cisplatin, as radiosensitizers in Strontium-89 therapy.  No clinically significant adverse effects or myelosuppression by platinum compounds were observed. In carboplatin study a pain response was observed in 74% of the evaluable patients. The pain response in the patients treated with 89Sr and carboplatin was clearly and significantly superior to that seen in the patients treated with 89Sr alone, whereas survival was only marginally better in the combined treatment group.  In the cisplatin study a pain response was observed in 83% of the evaluable patients. 
CONCLUSIONS: Low-dose platinum compounds seem to enhance the effects of 89Sr radioisotope therapy on pain from bone metastases without relevant hematological toxicity.  [Sciuto R, Festa A, et. al., Clin Ter 1998 Jan-Feb;149(921):43, PMID: 9621488 ]

        
About Strontium-89

To date, the best studied and most commonly used radionuclide is strontium-89. Its efficacy as first line therapy or as adjuvant to external beam radiotherapy has been documented.  

        "Strontium-89 is a pure beta-emitting radioisotope, a chemical analogue of calcium, and it is therefore avidly concentrated by areas of high osteoblastic activity. Selective uptake and prolonged retention at sites of increased bone mineral turnover provide precise bone lesions targeting. 89Sr chloride (commercialised as Metastron) is typically administered in a single 150 MBq parenteral dose. Its radioactive  emission poses very little radioprotection concerns. Overall, studies show pain relief in up to 80% of patients, of whom 10 to 40% became effectively pain free. The mean duration of palliation was 3-4 months.  The mechanism of pain relief is controversial; it is probably, but not only, related to the absorbed dose in the tumor and bone. There is no clear dose-response relationship. The only reported toxicity is temporary myelosuppression. WBC and platelets should be monitored at least on a weekly basis until they return to baseline. It seems that only patients with a reasonably good general condition stand to benefit from this treatment. In conclusion, systemic radionuclide therapy using 89Sr represents a feasible, safe, effective, well tolerated and cost-effective palliative treatment in patients with refractory bone pain." [118]


Because Sr-89 is a beta-emitting radionuclide with a long physical half-life (50.5 days), precautions should be taken by the caretaker(s) against Sr-89 contamination from the patient's blood or excretions, particularly if the patient is incontinent. PMID: 7545083

Pubmed search link:  Treatment of bone cancer with strontium-89.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=PubMed&term=bone%20strontium-89%20cancer%20treatment


About Samarium-153 


"Samarium-153-EDTMP is a 1:1 complex of radioactive Samarium-153 and a Tetraphosphonate [ethylenediamine-tetramethylene phosphonic acid (EDTMP)]. Samarium Sm-153-EDTMP has a high affinity for skeletal tissue and concentrates by chemiabsorption in areas of enhanced metabolic activity, where it associates with the hydroxyapatite crystal. Samarium-153 Lexidronam         [Quadramet (R)] has been approved for routine use by the FDA. This agent offers several advantages over other agents used for palliating bone pain. Due to its half-life of 46 hours and its beta emissions, a high dose rate can be delivered to regions adjacent to enhanced osteoblastic activity over a short period of time with little residual long term activity being left in the bone marrow. ... In addition, because it also emits a 103 keV gamma ray which makes it suitable for imaging and assessment of biodistribution, dosimetric applications are possible in the future."[11]

       
Samarium-153 ethylene diamine tetramethylene phosphonate [Samarium-153-EDTMP] is a beta particle and gamma ray emitting, bone-seeking radiopharmaceutical, and can provide therapeutic irradiation to osteoblastic [not osteoclastic or lytic] bone metastases [Osteoblasts are the bone cells that makes new bone]. It has been useful as an adjunct when treating some bony tumors with irradiation and polychemotherapy.  By itself, it is useful as a palliative agent for bone pain, and sometimes might slow development of metastases or slow tumor growth.  When the effect wears off, retreatment is possible. [3,4,6,37,39,47,49,56,59,60]


Benefit of Samarium-153 treatment in LMS is unknown, and unlikely to be more than palliative.  [3,4,6,37] Liver function tests were abnormal in some patients. [33]  
   

Pubmed search link:  Treatment of bone cancer with samarium-153.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=PubMed&term=bone%20samarium-153%20cancer%20treatment


About Rhenium-186      

  
In connection with our work on the development of 186Re-tetra-phosphonates with optimum properties for use in bone pain palliation, a novel cyclic tetraphosphonate derivative has been synthesized, complexed with 186Re and evaluated with promising results. The ligand consists of a cyclic array of tetra-aminomethylphosphonate groups. Biodistribution studies of the complex were performed. The results suggest the suitability of the complex for further evaluation in higher animals for bone pain palliation. [124]

        


Pubmed search link:  Treatment of bone cancer with rhenium-186.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=PubMed&term=bone%20rhenium-186%20cancer%20treatment



About Phosphorus-32

Can palliate pain and decrease tumor osteoblastic activity. It is given intravenously, and can be given repeatedly.  White count and platelet suppression can occur. [108]

Pubmed search link:  Treatment of bone cancer with phosphorus-32.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=PubMed&term=bone%20phosphorus-32%20cancer%20treatment




Some Comparisons


Strontium-89 and external beam hemibody and local radiotherapy

There was no significant difference in median survival.  All treatments provided effective pain relief; improvement was sustained to 3 months in 63.6% after hemibody radiotherapy compared with 66.1% after strontium-89, and in 61% after local radiotherapy compared with 65.9% in the strontium-89 group. Fewer patients reported new pain sites after strontium-89 than after local or hemibody radiotherapy (p < 0.05).   Radiotherapy to a new site was required by 12 patients in the local radiotherapy group compared with 2 after strontium-89 (p < 0.01), although there was no significant difference between hemibody radiotherapy (6 patients) and strontium-89 (9 patients) in this respect.  Platelets and leukocytes fell by an average 30-40% after strontium-89.[122]

89Sr appears as effective a treatment option as HBI. Response is most likely with either approach when patients have a good         performance status and a limited extent of disease. [123]


Strontium-89 and Samarium-153 
There is probably no difference in response rates between samarium-153 and strontium-89 radioisotopes as measured by the effect on pain or in the time to progression. [26]

Strontium-89, Radiation, and Bisphosphonate
Local radiotherapy completely prevents the incidence of secondary bone mets in PROSTATE cancer, (89)Sr leads to an important decrease in this complication and olpadronate induces a significant, albeit smaller decrease in the incidence of SCC. [109]      
              

Strontium-89 and Rhenium-186-HEDP
        "Retreatments showed significantly P<0.01) worse responses (48% levels 3+4), in comparison to first RTBM. "
        "Duration of palliation was 5.0+/-3.5 months, and was longer in cases of excellent response, in first RTBM, in patients with limited metastases and when 89Sr was used. Better responses were found in cases of limited skeletal disease, under good clinical conditions, when life expectancy exceeded 3 months, and in radiologically osteoblastic or mixed bone         lesions. The only statistically significant predictive factor was life expectancy (P<0.001). Flare phenomenon (14.1% of cases) did not correlate with the response. Haematological toxicity (mild to moderate in most cases) mainly affected platelets, and was observed in 25.5% of cases overall and in 38.9% of retreatments. RTBM did not seem to prolong life, though in some cases scintigraphic regression of bone metastases was observed. The two radiopharmaceuticals did not show any statistically significant differences in palliative efficacy and toxicity, either in first RTBM or in retreatments."   [109]
       

          "The global response rate was 84% for 89Sr and 92% for 186Re-HEDP. The onset of pain palliation appeared  significantly earlier in Rhenium group. The duration of pain relief ranged from two months to 14 months (mean of 125 days with a median value of 120 days) in Group A and from one month to 12 months (mean of 107 days with a median value of 60 days) in Group B (p = 0.39).  A moderate hematological toxicity was apparent in both groups. Platelet and white blood cell counts returned to baseline levels within 12 weeks after 89Sr administration and 6 weeks after 186Re-HEDP administration [significant]. CONCLUSIONS: Both 89Sr and 186Re-HEDP are effective and safe in bone pain palliation in breast cancer with the latter showing a significantly faster onset of pain relief." [110]

Strontium-89, Rhenium-188, and Rhenium-186-HEDP 
All three radiopharmaceuticals were effective in pain palliation. The various radionuclides had no significant difference in the pain relief or bone marrow impairment. [119]


Samarium-153 and Rhenium-186

The level of the long-lived radioisotope impurity burden in 153Samarium appears low enough not to pose a problem, and was almost two orders of magnitude lower than that of 186Rhenium [Samarium-153 one hundredth of the long-lived radioactive impurity load carried by Rhenium-186].  This is a notable overall advantage of 153Sm over the use of 186Rhenium. [5]



%%%%%%%%%%%%%%%%%%%%%%%%%%%
References:         


              3: Ozaki T, Flege S, Liljenqvist U, Hillmann A, Delling G, 
              Salzer-Kuntschik M, Jurgens H, Kotz R, Winkelmann W, Bielack 
              SS. 
        Osteosarcoma of the spine: experience of the Cooperative Osteosarcoma 
        Study Group.
        Cancer. 2002 Feb 15;94(4):1069-77.
        PMID: 11920477 [PubMed - indexed for MEDLINE]

              4: Anderson PM, Wiseman GA, Dispenzieri A, Arndt CA, Hartmann LC, 
              Smithson WA, Mullan BP, Bruland OS.

        High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low 
        toxicity of skeletal irradiation in patients with osteosarcoma and bone 
        metastases.
        J Clin Oncol. 2002 Jan 1;20(1):189-96.
        PMID: 11773169 [PubMed - indexed for MEDLINE]

              5: Ramamoorthy N, Saraswathy P, Das MK, Mehra KS, Ananthakrishnan 
              M.

        Production logistics and radionuclidic purity aspects of 153Sm for 
        radionuclide therapy.
        Nucl Med Commun. 2002 Jan;23(1):83-9.
        PMID: 11748442 [PubMed - indexed for MEDLINE]

              6: Franzius C, Bielack S, Flege S, Eckardt J, Sciuk J, Jurgens H, 
              Schober O.

        High-activity samarium-153-EDTMP therapy followed by autologous 
        peripheral blood stem cell support in unresectable osteosarcoma.
        Nuklearmedizin. 2001 Dec;40(6):215-20.
        PMID: 11797510 [PubMed - indexed for MEDLINE]



              8: Thurman SA, Ramakrishna NR, DeWeese TL.

        Radiation therapy for the treatment of locally advanced and metastatic 
        prostate cancer.
        Hematol Oncol Clin North Am. 2001 Jun;15(3):423-43. Review.
        PMID: 11525289 [PubMed - indexed for MEDLINE]

              9: Serafini AN.

        Therapy of metastatic bone pain.
        J Nucl Med. 2001 Jun;42(6):895-906. Review.
        PMID: 11390554 [PubMed - indexed for MEDLINE]

              11: Serafini AN.

        Systemic metabolic radiotherapy with samarium-153 EDTMP for the 
        treatment of painful bone metastasis.
        Q J Nucl Med. 2001 Mar;45(1):91-9. Review.
        PMID: 11456381 [PubMed - indexed for MEDLINE]


              13: Brenner W, Kampen WU, Kampen AM, Henze E.

        Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP 
        in patients with metastatic bone disease.
        J Nucl Med. 2001 Feb;42(2):230-6.
        PMID: 11216521 [PubMed - indexed for MEDLINE]


              15: Silberstein EB, Eugene L, Saenger SR.

        Painful osteoblastic metastases: the role of nuclear medicine.
        Oncology (Huntingt). 2001 Feb;15(2):157-63; discussion 167-70, 174. 
        Review.
        PMID: 11252931 [PubMed - indexed for MEDLINE]

          
              20: Silberstein EB.

        Systemic radiopharmaceutical therapy of painful osteoblastic metastases.
        Semin Radiat Oncol. 2000 Jul;10(3):240-9. Review.
        PMID: 11034634 [PubMed - indexed for MEDLINE]

              21: Serafini AN.

        Samarium Sm-153 lexidronam for the palliation of bone pain associated 
        with metastases.
        Cancer. 2000 Jun 15;88(12 Suppl):2934-9. Review.
        PMID: 10898337 [PubMed - indexed for MEDLINE]

              23: McEwan AJ.

        Use of radionuclides for the palliation of bone metastases.
        Semin Radiat Oncol. 2000 Apr;10(2):103-14. Review.
        PMID: 10727599 [PubMed - indexed for MEDLINE]

              25: Klutmann S, Bohuslavizki KH.

        [Palliation of bone pain in metastatic prostate carcinoma. Value of 
        radionuclide therapy with rhenium 186 HEDP]
        MMW Fortschr Med. 1999 Nov 4;141(44):38-9. German.
        PMID: 10912142 [PubMed - indexed for MEDLINE]

              26: Dickie GJ, Macfarlane D.

        Strontium and samarium therapy for bone metastases from prostate 
        carcinoma.
        Australas Radiol. 1999 Nov;43(4):476-9.
        PMID: 10901963 [PubMed - indexed for MEDLINE]

              28: Papatheofanis FJ.

        Variation in oncologic opinion regarding management of metastatic bone 
        pain with systemic radionuclide therapy.
        J Nucl Med. 1999 Sep;40(9):1420-3.
        PMID: 10492359 [PubMed - indexed for MEDLINE]

              29: Cameron PJ, Klemp PF, Martindale AA, Turner JH.

        Prospective 153Sm-EDTMP therapy dosimetry by whole-body scintigraphy.
        Nucl Med Commun. 1999 Jul;20(7):609-15.
        PMID: 10423762 [PubMed - indexed for MEDLINE]

]

              33: Tian JH, Zhang JM, Hou QT, Oyang QH, Wang JM, Luan ZS, Chuan 
              L, He YJ.

        Multicentre trial on the efficacy and toxicity of single-dose 
        samarium-153-ethylene diamine tetramethylene phosphonate as a palliative 
        treatment for painful skeletal metastases in China.
        Eur J Nucl Med. 1999 Jan;26(1):2-7.
        PMID: 9933654 [PubMed - indexed for MEDLINE]

              34: Franzius C, Bielack S, Sciuk J, Vollet B, Jurgens H, Schober 
              O.

        High-activity samarium-153-EDTMP therapy in unresectable osteosarcoma.
        Nuklearmedizin. 1999;38(8):337-40.
        PMID: 10615669 [PubMed - indexed for MEDLINE]

              35: van Rensburg AJ, Alberts AS, Louw WK.

        Quantifying the radiation dosage to individual skeletal lesions treated 
        with samarium-153-EDTMP.
        J Nucl Med. 1998 Dec;39(12):2110-5.
        PMID: 9867152 [PubMed - indexed for MEDLINE]

              36: Coleman RE.

        How can we improve the treatment of bone metastases further?
        Curr Opin Oncol. 1998 Aug;10 Suppl 1:S7-13. Review.
        PMID: 9801853 [PubMed - indexed for MEDLINE]

              37: Lovera C, Massardo T, Galleguillos MC, Gonzalez P, Comparini 
              B, Yanez M, Fodor M, Gil MC, Araya G, Tomicic M.

        [Analgesic response and secondary effects in patients with osteoblastic 
        metastasis, treated with Samarium 153 
        ethylenediaminotetramethylenephosphate]
        Rev Med Chil. 1998 Aug;126(8):963-71. Spanish.
        PMID: 9830748 [PubMed - indexed for MEDLINE]

              38: Knapp FF Jr, Mirzadeh S, Beets AL, O'Doherty M, Blower PJ, 
              Verdera ES, Gaudiano JS, Kropp J, Guhlke J, Palmedo H, Biersack 
              HJ.

        Reactor-produced radioisotopes from ORNL for bone pain palliation.
        Appl Radiat Isot. 1998 Apr;49(4):309-15.
        PMID: 9519440 [PubMed - indexed for MEDLINE]

              39: Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, 
              Bertrand A, Ahmann FR, Orihuela E, Reid RH, Lerski RA, Collier BD, 
              McKillop JH, Purnell GL, Pecking AP, Thomas FD, Harrison 
              KA.

        Palliation of pain associated with metastatic bone cancer using 
        samarium-153 lexidronam: a double-blind placebo-controlled clinical 
        trial.
        J Clin Oncol. 1998 Apr;16(4):1574-81.
        PMID: 9552068 [PubMed - indexed for MEDLINE]


              47: Resche I, Chatal JF, Pecking A, Ell P, Duchesne G, Rubens R, 
              Fogelman I, Houston S, Fauser A, Fischer M, Wilkins D.Related 
              Articles

        A dose-controlled study of 
        153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment 
        of patients with painful bone metastases.
        Eur J Cancer. 1997 Sep;33(10):1583-91.
        PMID: 9389919 [PubMed - indexed for MEDLINE]

              49: Alberts AS, Smit BJ, Louw WK, van Rensburg AJ, van Beek A, 
              Kritzinger V, Nel JS.

        Dose response relationship and multiple dose efficacy and toxicity of 
        samarium-153-EDTMP in metastatic cancer to bone.
        Radiother Oncol. 1997 May;43(2):175-9.
        PMID: 9192964 [PubMed - indexed for MEDLINE]

              50: McEwan AJ.

        Unsealed source therapy of painful bone metastases: an update.
        Semin Nucl Med. 1997 Apr;27(2):165-82. Review.
        PMID: 9144858 [PubMed - indexed for MEDLINE]

              51: Ben-Josef E, Porter AT.

        Radioisotopes in the treatment of bone metastases.
        Ann Med. 1997 Feb;29(1):31-5. Review.
        PMID: 9073322 [PubMed - indexed for MEDLINE]


              53: Lewington VJ.

        Cancer therapy using bone-seeking isotopes.
        Phys Med Biol. 1996 Oct;41(10):2027-42. Review.
        PMID: 8912378 [PubMed - indexed for MEDLINE]

              55: Atkins HL, Srivastava SC.

        Radiolabeled bone-seeking radiopharmaceuticals.
        Q J Nucl Med. 1996 Sep;40(3):285-9. Review.
        PMID: 8961805 [PubMed - indexed for MEDLINE]

              56: Olea E, Gil MC, Tomicic M, Araya G, Chandia M, Quintana JC, 
              Pinto L, Orellana P, Nagel J, Ortiz V.

        [Nationally produced 153SmEDTMP in the palliative treatment of 
        metastatic bone cancer pain]
        Rev Med Chil. 1996 Jul;124(7):805-12. Spanish.
        PMID: 9138368 [PubMed - indexed for MEDLINE]

              59: Bruland OS, Skretting A, Solheim OP, Aas M.

        Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new 
        promising approach.
        Acta Oncol. 1996;35(3):381-4.
        PMID: 8679270 [PubMed - indexed for MEDLINE]

              60: Deng H, Luo S, Tan T, Mo T, Liang Z, Pu M, Jiao J, Zhong S, 
              Wang Q, Hu Y, et al.

        [153Sm-EDTMP for moderate and severe bone cancer pain]
        Hua Xi Yi Ke Da Xue Xue Bao. 1995 Dec;26(4):391-4. Chinese.
        PMID: 8732058 [PubMed - indexed for MEDLINE]

              61: Robinson RG, Preston DF, Schiefelbein M, Baxter KG.Related 
              Articles

        Strontium 89 therapy for the palliation of pain due to osseous 
        metastases.
        JAMA. 1995 Aug 2;274(5):420-4. Review.
        PMID: 7542352 [PubMed - indexed for MEDLINE]

              62: Deng H, Tan T, Mo T, Zhong S, Kuan A, Hu Y.

        [Effect of 153Sm-EDTMP on hematopoiesis and vital organs of 93 patients 
        with bone tumor]
        Hua Xi Yi Ke Da Xue Xue Bao. 1995 Jun;26(2):155-9. Chinese.
        PMID: 7490021 [PubMed - indexed for MEDLINE]

              64: Serafini AN.

        Current status of systemic intravenous radiopharmaceuticals for the 
        treatment of painful metastatic bone disease.
        Int J Radiat Oncol Biol Phys. 1994 Dec 1;30(5):1187-94. Review.
        PMID: 7525518 [PubMed - indexed for MEDLINE]

              65: Ahonen A, Joensuu H, Hiltunen J, Hannelin M, Heikkila J, 
              Jakobsson M, Jurvelin J, Kairemo K, Kumpulainen E, Kulmala J, et 
              al.

        Samarium-153-EDTMP in bone metastases.
        J Nucl Biol Med. 1994 Dec;38(4 Suppl 1):123-7.
        PMID: 7543288 [PubMed - indexed for MEDLINE]

              66: Porter AT, Ben-Josef E, Davis L.

        Systemic administration of new therapeutic radioisotopes, including 
        phosphorus, strontium, samarium, and rhenium.
        Curr Opin Oncol. 1994 Nov;6(6):607-10. Review.
        PMID: 7827173 [PubMed - indexed for MEDLINE]

              67: Jiang CY, Zhu BL, Zhang YJ.

        [The value of Sm-153-EDTMP for treatment of metastatic bone pain and 
        improving quality of life]
        Zhonghua Zhong Liu Za Zhi. 1994 Mar;16(2):118-21. Chinese.
        PMID: 7523052 [PubMed - indexed for MEDLINE]

              68: Schott ME, Schlom J, Siler K, Milenic DE, Eggensperger D, 
              Colcher D, Cheng R, Kruper WJ Jr, Fordyce W, Goeckeler W.Related 
              Articles

        Biodistribution and preclinical radioimmunotherapy studies using 
        radiolanthanide-labeled immunoconjugates.
        Cancer. 1994 Feb 1;73(3 Suppl):993-8.
        PMID: 8306291 [PubMed - indexed for MEDLINE]

              69: Porter AT, Davis LP.

        Systemic radionuclide therapy of bone metastases with strontium-89.
        Oncology (Huntingt). 1994 Feb;8(2):93-6; discussion 96, 99-101.
        PMID: 8167090 [PubMed - indexed for MEDLINE]


              72: Bayouth JE, Macey DJ, Kasi LP, Fossella FV.

        Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain 
        due to skeletal metastases.
        J Nucl Med. 1994 Jan;35(1):63-9.
        PMID: 7505819 [PubMed - indexed for MEDLINE]

              73: Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf 
              S, Livingston RB, Gordon EE, Chapman CR, Appelbaum FR.Related 
              Articles

        Samarium-153-EDTMP in bone metastases of hormone refractory prostate 
        carcinoma: a phase I/II trial.
        J Nucl Med. 1993 Nov;34(11):1839-44.
        PMID: 8229221 [PubMed - indexed for MEDLINE]


              75: Eary JF, Collins C, Stabin M, Vernon C, Petersdorf S, Baker M, 
              Hartnett S, Ferency S, Addison SJ, Appelbaum F, et al.Related 
              Articles

        Samarium-153-EDTMP biodistribution and dosimetry estimation.
        J Nucl Med. 1993 Jul;34(7):1031-6.
        PMID: 7686217 [PubMed - indexed for MEDLINE]

              76: Goeckeler WF, Stoneburner LK, Kasi LP, Fossella FV, Price DR, 
              Fordyce WA.

        Analysis of urine samples from metastatic bone cancer patients 
        administered 153Sm-EDTMP.
        Nucl Med Biol. 1993 Jul;20(5):657-61.
        PMID: 8358352 [PubMed - indexed for MEDLINE]

              77: Holmes RA.

        Radiopharmaceuticals in clinical trials.
        Semin Oncol. 1993 Jun;20(3 Suppl 2):22-6. Review.
        PMID: 7684861 [PubMed - indexed for MEDLINE]

              79: Lewington VJ.

        Targeted radionuclide therapy for bone metastases.
        Eur J Nucl Med. 1993 Jan;20(1):66-74. Review.
        PMID: 7678397 [PubMed - indexed for MEDLINE]

              81: Farhanghi M, Holmes RA, Volkert WA, Logan KW, Singh A.Related 
              Articles

        Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an 
        escalating dose schedule in treatment of metastatic bone cancer.
        J Nucl Med. 1992 Aug;33(8):1451-8.
        PMID: 1378887 [PubMed - indexed for MEDLINE]

              82: Sandeman TF, Budd RS, Martin JJ.

        Samarium-153-labelled EDTMP for bone metastases from cancer of the 
        prostate.
        Clin Oncol (R Coll Radiol). 1992 May;4(3):160-4.
        PMID: 1375094 [PubMed - indexed for MEDLINE]

              84: Robinson RG, Preston DF, Spicer JA, Baxter KG.

        Radionuclide therapy of intractable bone pain: emphasis on strontium-89.
        Semin Nucl Med. 1992 Jan;22(1):28-32. Review.
        PMID: 1589803 [PubMed - indexed for MEDLINE]

              85: Holmes RA.

        [153Sm]EDTMP: a potential therapy for bone cancer pain.
        Semin Nucl Med. 1992 Jan;22(1):41-5. Review.
        PMID: 1589805 [PubMed - indexed for MEDLINE]


              88: Turner JH, Claringbold PG.

        A phase II study of treatment of painful multifocal skeletal metastases 
        with single and repeated dose samarium-153 ethylenediaminetetramethylene 
        phosphonate.
        Eur J Cancer. 1991;27(9):1084-6.
        PMID: 1720321 [PubMed - indexed for MEDLINE]

              95: Goodman JH, Gahbauer RA, Kanellitsas C, Clendenon NR, Laster 
              BH, Fairchild RG.

        Theoretical basis and clinical methodology for stereotactic interstitial 
        brain tumor irradiation using iododeoxyuridine as a radiation sensitizer 
        and 145Sm as a brachytherapy source.
        Stereotact Funct Neurosurg. 1990;54-55:531-4.
        PMID: 1964244 [PubMed - indexed for MEDLINE]

              96: Turner JH, Claringbold PG, Hetherington EL, Sorby P, 
              Martindale AA.

        A phase I study of samarium-153 ethylenediaminetetramethylene 
        phosphonate therapy for disseminated skeletal metastases.
        J Clin Oncol. 1989 Dec;7(12):1926-31.
        PMID: 2585026 [PubMed - indexed for MEDLINE]

              97: Singh A, Holmes RA, Farhangi M, Volkert WA, Williams A, 
              Stringham LM, Ketring AR.

        Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer.
        J Nucl Med. 1989 Nov;30(11):1814-8.
        PMID: 2478681 [PubMed - indexed for MEDLINE]

              99: Turner JH, Martindale AA, Sorby P, Hetherington EL, Fleay RF, 
              Hoffman RF, Claringbold PG.

        Samarium-153 EDTMP therapy of disseminated skeletal metastasis.
        Eur J Nucl Med. 1989;15(12):784-95.
        PMID: 2483138 [PubMed - indexed for MEDLINE]

              100: Fairchild RG, Kalef-Ezra J, Packer S, Wielopolski L, Laster 
              BH, Robertson JS, Mausner L, Kanellitsas C.

        Samarium-145: a new brachytherapy source.
        Phys Med Biol. 1987 Jul;32(7):847-58.
        PMID: 3615583 [PubMed - indexed for MEDLINE]

              101: Logan KW, Volkert WA, Holmes RA.

        Radiation dose calculations in persons receiving injection of 
        samarium-153 EDTMP.
        J Nucl Med. 1987 Apr;28(4):505-9.
        PMID: 3572536 [PubMed - indexed for MEDLINE]

              102: Ketring AR.

        153Sm-EDTMP and 186Re-HEDP as bone therapeutic radiopharmaceuticals.
        Int J Rad Appl Instrum B. 1987;14(3):223-32.
        PMID: 3117736 [PubMed - indexed for MEDLINE]

              103: Goeckeler WF, Troutner DE, Volkert WA, Edwards B, Simon J, 
              Wilson D.

        153Sm radiotherapeutic bone agents.
        Int J Rad Appl Instrum B. 1986;13(4):479-82.
        PMID: 3793505 [PubMed - indexed for MEDLINE]


              107: Muller WA, Schaffer EH, Linzner U.

        Studies on incorporated short-lived beta-emitters with regard to the 
        induction of late effects.
        Radiat Environ Biophys. 1980;18(1):1-11.
        PMID: 6934560 [PubMed - indexed for MEDLINE]


              108: Shah Syed GM, Maken RN, Muzzaffar N, Shah MA, Rana F.

        Effective and economical option for pain palliation in prostate cancer 
        with skeletal metastases: 32P therapy revisited.
        Nucl Med Commun 1999 Aug;20(8):697-702
        PMID: 10451877 [PubMed - indexed for MEDLINE]
        
109: Akerley W, Butera J, Wehbe T, Noto R, Stein B, Safran H, 
              Cummings F, Sambandam S, Maynard J, Di Rienzo G, Leone L.

        A multiinstitutional, concurrent chemoradiation trial of strontium-89, 
        estramustine, and vinblastine for hormone refractory prostate carcinoma 
        involving bone.
        Cancer. 2002 Mar 15;94(6):1654-60.
        PMID: 11920525 [PubMed - indexed for MEDLINE]

109: Windsor PM.

        Predictors of response to strontium-89 (Metastron) in skeletal 
        metastases from prostate cancer: report of a single centre's 10-year 
        experience.
        Clin Oncol (R Coll Radiol). 2001;13(3):219-27.
        PMID: 11527299 [PubMed - indexed for MEDLINE]

110: Dafermou A, Colamussi P, Giganti M, Cittanti C, Bestagno M, 
              Piffanelli A.

        A multicentre observational study of radionuclide therapy in patients 
        with painful bone metastases of prostate cancer.
        Eur J Nucl Med. 2001 Jul;28(7):788-98.
        PMID: 11504074 [PubMed - indexed for MEDLINE]

117: Blake GM, Zivanovic MA, McEwan AJ, Condon BR, Ackery DM.
          
        Strontium-89 therapy: strontium kinetics and dosimetry in two patients 
        treated for metastasising osteosarcoma.
        Br J Radiol 1987 Mar;60(711):253-9
        
118: Giammarile F, Mognetti T, Resche I.

        Bone pain palliation with strontium-89 in cancer patients with bone 
        metastases.
        Q J Nucl Med. 2001 Mar;45(1):78-83. Review.
        PMID: 11456379 [PubMed - indexed for MEDLINE]

119: Fuster D, Herranz R, Alcover J, Mateos JJ, Martin F, 
              Vidal-Sicart S, Pons F.

        [Treatment of metastatic bone pain with repeated doses of strontium-89 
        in patients with prostate neoplasm]
        Rev Esp Med Nucl. 2000 Aug;19(4):270-4. Spanish.
        PMID: 11062097 [PubMed - indexed for MEDLINE]


120: Silberstein EB.

        Systemic radiopharmaceutical therapy of painful osteoblastic metastases.
        Semin Radiat Oncol 2000 Jul;10(3):240-9 
        PMID: 11034634 [PubMed - indexed for MEDLINE]
     

      121: Kossman SE, Weiss MA.        

        Acute myelogenous leukemia after exposure to strontium-89 for the 
        treatment of adenocarcinoma of the prostate.
        Cancer 2000 Feb 1;88(3):620-4 

        
122: Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, Reed 
                    NS, Russell JM, Yardley J.

        A comparison of the palliative effects of strontium-89 and external beam 
        radiotherapy in metastatic prostate cancer.
        Radiother Oncol 1994 Apr;31(1):33-40   


              123: Dearnaley DP, Bayly RJ, A'Hern RP, Gadd J, Zivanovic MM, Lewington VJ.

        Palliation of bone metastases in prostate cancer. Hemibody irradiation 
        or strontium-89?
        Oncol (R Coll Radiol) 1992 Mar;4(2):101-7
        PMID: 1372817 [PubMed - indexed for MEDLINE]


124: Kothari K, Samuel G, Banerjee S, Unni PR, Sarma HD, Chaudhari PR, 
        Unnikrishnan TP, Pillai MR.
       
        186Re-1,4,8,11-tetraaza cyclotetradecyl-1,4,8,11-tetramethylene 
        phosphonic acid: a novel agent for possible use in metastatic bone-pain 
        palliation. Nucl Med Biol 2001 Aug;28(6):709-17 
    PMID: 11518653 [PubMed - indexed for MEDLINE] 
  

        125: Berk L. 

        Prospective trials for the radiotherapeutic treatment of bone 
        metastases. 
        Am J Hosp Palliat Care 1995 Jul-Aug;12(4):24-8  
        PMID: 7543272  indexed for MEDLINE


    126: Powsner RA, Zietman AL, Foss FM.

        Bone marrow suppression after strontium-89 therapy and local radiation 
        therapy in patients with diffuse marrow involvement.
        Clin Nucl Med 1997 Mar;22(3):147-50  
        PMID: 9067666 [PubMed - indexed for MEDLINE]



Radiotherapy


        Targeting of radiotherapy can be based on improving physical dose distribution of radiation delivered or on utilization of specific biological processes for targeting. Tools for physical targeting include Brach therapy, hadron therapy, conformal radiotherapy, stereotactic radiotherapy, stereotactically guided conformal fractionated radiotherapy, and intensity-modulated radiotherapy. Biological targeting can be based on specific metabolic pathways such as uptake of iodine-131 by thyroid cancer cells, difference in substrate uptake between cancer cells and normal cells (e.g. boronophenylalanine in boron neutron capture therapy), targeting of radioactive isotopes by specific carrier molecules (radioimmunotherapy, labeled hormone derivatives or bone-seeking phosphonates), or on the distribution of elements in the         body (therapy of bone metastases with a calcium analog strontium-89 or phosphorus-32). [29]

Painful bone metastases are common in oncologic practice. The role of surgery should be limited to patients with neurologic compression or severe mechanical instability. [102]  Ninety percent of patients with symptomatic bone metastases obtain some pain relief with a low dose, brief course of palliative radiotherapy. One half of the responding patients may experience complete pain relief. A single dose of 800 cGy in the setting of painful bone metastasis may provide pain control comparable to more protracted treatment at a higher dose of radiation. [80] There seem to be no significant differences in pain relief between the different fractionation schedules. A palliation is ensured in 75% of all cases with a partial response of 42% and complete response of 33%. With regard to pain response these results do not justify a recommendation for a standard fractionation schedule. Current fractionation schedules such as 10 x 3 Gy for 2 weeks or 5 x 4 Gy for 1 week should probably be used.[53]   In one study, two short courses of radiation for bone pain were compared: 20 Gy in one week (daily dose 4 Gy), and 30 Gy in 3 weeks (daily dose 2 Gy).  There was a light trend favoring 30 Gy in frequency of pain relief and recalcification. [78] However, it is not known whether these short radiation schedules are adequate for patients with longer prognoses, or what the optimal fractionation schedule is for maintaining the structural integrity of the bone.

For patients with symptomatic widespread bone metastases, options include bisphosphonates or radiotherapy.  There are two forms of systemic radiotherapy available: hemibody irradiation and intravenous injection of radionuclides. Studies have shown the combination of either focal irradiation and hemibody irradiation or focal irradiation and the injection of strontium-89 prolongs the pain-free duration of the patients. [80,100,125]   HBI is a powerful palliative treatment in patients with multiple symptomatic bone metastases.  Analysis of one study of 78 procedures on 71 patients, treated with 6 Gy (upper half-body) or 8 Gy (lower half-body) HBI in single fraction: Complete (37.5%) or partial responses were observed in 72/78 (92.3%) procedures, 80% appearing during the first 72 hours. A mean response duration of 101 days over a mean overall survival of 141 days implies coverage of 70% of patient's life span.  [72]
A slower development of motor deficits before beginning of radiotherapy means a better therapeutic effect and a more favorable functional outcome after treatment. The prognosis is extraordinarily poor if severe deterioration of motor function occurs within 48 hours before radiotherapy.  [54]
A meta-analysis of the literature on Radiotherapy for Skeletal Metastases was done in 1996. It was based on 171 scientific articles involving over 13,000 patients, and states:   "Radiotherapy has been well documented as a method for alleviating pain, but the mechanisms underlying this effect are largely unknown. When used for pain palliation, radiotherapy achieves freedom from pain, or substantial alleviation of pain in nearly all cases, with few side effects. Half-body irradiation is effective in treating multiple metastatic sites and should be considered for use more frequently. However, this increases the requirements on equipment, dosimetry, and hospital beds. Systemic radiotherapy with radionuclides may be indicated for generalized skeletal pain. The role of radiotherapy in preventing or healing fractures is not fully evaluated. Optimum dose levels and fractionation schedules have not been established. Early radiotherapy for spinal cord compression may prevent symptoms from worsening, but the effects on existing paralysis are modest." [55] 
"Local radiotherapy plays an important and responsible role in the management of bone metastases according to the different treatment objectives in the sense of pain relief, remineralization and cord decompression. Radiotherapy schedules, aimed at the relief of pain, need to take into consideration life expectancy. Patients with a reduced life expectancy could have a good high chance of achieving pain relief with a single dose of 8 Gy. Patients with a solitary metastasis, patients with a longer life expectancy and patients with a pathological fracture should be treated with 'curative' irradiation doses, aimed at killing the maximum number of tumor cells. In addition to pain relief, remineralization is also an important treatment goal. Conventional radiotherapy with doses of 40-50 Gy resulted in pain relief in 70-100% and in remineralization in 60-80% of the patients. Remineralization could not be accelerated by short-course fractionation courses, but resulted in faster pain relief. Short-course fractionation schedules are not indicated as a 'standard' treatment in the vertebral column. Surgery is the treatment of choice for immediate cord decompression and stabilization of a pathological vertebral fracture. Radiotherapy alone could decrease neurological impairment and is suitable for patients with gradual onset and progression of symptoms, no spinal instability and lesions of the cauda equina." [134]
Intensity and severity of radiation-induced nausea and emesis depend on a number of factors including irradiation site, irradiation dose, treatment field (width and length), and age of the patients. Although less intensive than that induced by chemotherapy, during protracted courses of fractionated radiotherapy discomfort can be substantial. As early as 1953, Court-Brown [2] described characteristic symptoms after single-fraction radiotherapy as "acute irradiation syndrome": irradiation was followed by asymptomatic period of 40-90 minutes, after that the patient experienced an acute episode of emesis, usually without preceding nausea. After a period of relative stabilization, additional episodes of emesis occurred for six hours after irradiation, decreasing its intensity with time. Danjoux et al. [5] noted a higher incidence of radiation-induced emesis after the upper half-body irradiation (UHBI) than after the lower half-body irradiation (LHBI), lack of efficacy of antiemetics administered, and similar response to emesis after the lower or the upper half-body irradiation. These results suggested that critical area was the upper abdomen. [117]


For Pubmed search on Treatment of Bone Metastases with Radiotherapy:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=PubMed&term=bone%20metastases%20radiotherapy%20treatment



Go To Top

References:

29: Joensuu H, Tenhunen M.
      
        Physical and biological targeting of radiotherapy.
        Acta Oncol 1999;38 Suppl 13:75-83 
        PMID: 10612500 [PubMed - indexed for MEDLINE]


 	53: Koswig S, Buchali A, Bohmer D, Schlenger L, Budach V.  

      [Palliative radiotherapy of bone metastases. A retrospective analysis of 176 patients] [Article in German] 
      Strahlenther Onkol 1999 Oct;175(10):509-14
      PMID: 10554646 [PubMed - indexed for MEDLINE] 


54: Rades D, Blach M, Nerreter V, Bremer M, Karstens JH

      Metastatic spinal cord compression. Influence of time between onset of motoric deficits and start of irradiation on therapeutic effect. 
      Strahlenther Onkol 1999 Aug;175(8):378-81
      PMID: 10481768 [PubMed - indexed for MEDLINE]


55: Moller T.

Acta Oncol 1996;35 Suppl 7:125-36 
Skeletal metastases. 
PMID: 9154105 [PubMed - indexed for MEDLINE] 


72: Algara M, Valls A, Ruiz V, Jaume M, Lacruz M, Foro P.

[Half-body irradiation. Palliative efficacy and predictive factors of response in 78 procedures] [Article in Spanish] 
Med Clin (Barc) 1994 Jun 18;103(3):85-8
PMID: 8065222 [PubMed - indexed for MEDLINE]


78: Niewald M, Tkocz HJ, Abel U, Scheib T, Walter K, Nieder C, Schnabel K, Berberich W, Kubale R, Fuchs M.

Rapid course radiation therapy vs. more standard treatment: a randomized trial for bone metastases. 
Int J Radiat Oncol Biol Phys 1996 Dec 1;36(5):1085-9 
PMID: 8985030 [PubMed - indexed for MEDLINE] 

              80:  Hoegler D.

        Radiotherapy for palliation of symptoms in incurable cancer.
        Curr Probl Cancer 1997 May-Jun;21(3):129-83
        PMID: 9202888 [PubMed - indexed for MEDLINE] 


                	100: Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, Reed 
        NS, Russell JM, Yardley J. 

        A comparison of the palliative effects of strontium-89 and external beam 
        radiotherapy in metastatic prostate cancer.
        Radiother Oncol 1994 Apr;31(1):33-40
        PMID: 7518932 [PubMed - indexed for MEDLINE] 

102: Micheletti E, Ippolito V, Tonoli S, Barbera F, Saccalani M. 

[Is radiotherapy still the first choice treatment in spinal metastases from breast cancer?] [Article in Italian] 
Radiol Med (Torino) 1996 Oct;92(4):470-4 
PMID: 9045251 [PubMed - indexed for MEDLINE] 

117: Jeremic B.   

[Ondansetron in the prevention of radiation-induced nausea and emesis in patients treated with single-fraction irradiation] [Article in Serbo-Croatian (Cyrillic)]   
Srp Arh Celok Lek 1996 May-Jun;124(5-6):131-4 
PMID: 9102832 [PubMed - indexed for MEDLINE]

      		125: Berk L. 

        Prospective trials for the radiotherapeutic treatment of bone 
        metastases. 
        Am J Hosp Palliat Care 1995 Jul-Aug;12(4):24-8  
        PMID: 7543272  indexed for MEDLINE

134: Eble MJ, Eckert W, Wannenmacher M 

[Value of local radiotherapy in treatment of osseous metastases, pathological fractures and spinal cord compression] [Article in German] 
Radiologe 1995 Jan;35(1):47-54 
PMID: 7534426 [PubMed - indexed for MEDLINE




Go To Top           






